START (Strategic Timing of AntiRetroviral Treatment) is an international randomized trial to determine whether starting antiretroviral therapy (ART) early (before CD4 drops to less than 500 cells/mm³), rather than waiting until CD4 drops to less than 350 cells/mm³ (when evidence from randomized trials supports starting ART), reduces the occurrence of serious morbidity and mortality. START began enrollment in April 2009 and is currently being carried out at 229 clinics in 35 countries around the world. The enrollment goal of the 4,600 participants was reached in December 2013. Follow-up is expected to continue until the end of 2016.START EudraCT number: 2008-006439-12.
For additional information about the study please contact CHIP:
Rigshospitalet, University of Copenhagen
CHIP, Department of Infectious Diseases, Section 2100
DK-2100 Copenhagen Ø, Denmark
Tel: +45 35 45 57 57
Fax: +45 35 45 57 58
For further details about the trial go to the INSIGHT website and click on HIV studies.